1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 15th April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Tevogen Bio to investigate T cell therapy in long Covid

Discussion in 'Long Covid news' started by John Mac, Nov 23, 2022.

  1. John Mac

    John Mac Senior Member (Voting Rights)

    Messages:
    926
    Tevogen Bio is set to study the potential therapeutic use of its investigational Covid-19 T cell therapy, TVGN-489, in long Covid. The finding that none of the patients in the TVGN 489 proof-of-concept (POC) trial, treated for their initial Covid infection, developed long Covid to date is leading Tevogen to explore the potential of TVGN 489 to also treat long Covid.

    “I’m greatly encouraged by the POC trial experience of TVGN 489 and hopeful that our investigational Covid-19 therapy will eventually offer hope to a substantial segment of Long Covid patients,” said Neal Flomenberg, Tevogen’s chief scientific officer.

    “Anyone that knows someone who has been impacted by this debilitating disease understands the importance of advancing science to alleviate the suffering from long Covid,” said Tevogen CEO Ryan Saadi.

    “I’m hopeful that our innovative T cell technology will eventually offer accessible immunotherapies to millions suffering from viral infections, cancers and other diseases with high unmet need.”

    TVGN-489 is highly purified cytotoxic CD8+ T lymphocytes (CTLs) designed to detect and kill SARS-CoV-2 infected cells. These allogeneic genetically unmodified CTLs are enriched and expanded in the lab and recognize proteins from across the entire SARS-CoV-2 genome, not just the spike protein.

    In July 2022, TVGN-489 completed POC clinical trial enrollment with zero treatment-related adverse events. Patients treated were infected with a range of all Covid variants at the time, from Delta through Omicron BA.5. Additionally, each patient had co-morbidities rendering them high risk and 50% of those additionally met the definition of being immunocompromised.

    https://www.labiotech.eu/trends-news/tevogen-bio-investigate-t-cell-therapy-long-covid/
     
    Last edited: Nov 23, 2022
    Jacob Richter, EzzieD, RedFox and 4 others like this.
  2. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    12,464
    Location:
    Canada
    Whatever the real answer happens to be, if it's all about the T-cells it would make such an iconic moment of Wessely's "enough with the T-cells".

    Doubtful that any one thing is the whole answer, but this would be in the same vein as "bacteria can't possibly survive in the stomach" and peptic ulcers, the once quintessential psychosomatic disorder, which would still be considered as such without Marshall's work. If only lessons were learned out of this exact same parallel mistake. If only lessons could be learned at all.
     

Share This Page